Vaccines for covid-19 patients
We are currrently developing the protocol for the systematic review on vaccines at the same time we are searching the literature every day and collecting data for candidate vaccines against COVID-19.
Below you can access all the vaccine comparisons where data are available as well as a table with the general characteristics and the risk of bias assessment of each trial. The forest plots, evidence profile and Summary of Findings (SoF) for all the outcomes of interest will be presented soon.
We have identified nine vaccine trials so far, data from these trials are under extraction and will be presented on this page.
The evidence synthesis will be added respectively.
Treatment comparisons
We report below the forest plots for the main treatment comparisons.
Please choose a Treatment Comparison:
Reboot the table and see all comparisons
- Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Placebo
- Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Adenovirus type-5-vectored COVID-19 5×10¹° vp
- Adenovirus type-5-vectored COVID-19 5×10¹° vp vs Placebo
Description of primary studies
In this table, we report the main characteristics of the Vaccine RCTs identified.
The link in the column Overall risk of bias will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement. The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column Full description will give you access to the general characteristics of the study.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
| NCT04324606 Folegatti PM, Lancet, 2020 Full text Commentary |
Mixed (Sponsor: University of Oxford ) |
ChAdOx1 | MenACWY | RCT | Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK | N=1077 |
Some concerns Details |
|
| NCT04368988 Keech C., N Engl J Med, 2020 Full text Commentary |
Mixed (Sponsor:Novavax) |
2 dose 25μg NVX-D0/21 | Placebo | RCT | Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. | N=134 |
Some concerns Details |
|
| 2 dose 5μg NVX/M1-D0/21 | Placebo | |||||||
| 2 dose 25μg NVX/M1-D0/21 | Placebo | |||||||
| 1 dose 25μg NVX/M1+Placebo-D0/21 | Placebo | |||||||
| 2 dose 25μg NVX-D0/21 | 2 dose 5μg NVX/M1-D0/21 | |||||||
| 2 dose 25μg NVX-D0/21 | 2 dose 25μg NVX/M1-D0/21 | |||||||
| 2 dose 25μg NVX-D0/21 | 1 dose 25μg NVX/M1+Placebo-D0/21 | |||||||
| 2 dose 5μg NVX/M1-D0/21 | 2 dose 25μg NVX/M1-D0/21 | |||||||
| 2 dose 5μg NVX/M1-D0/21 | 1 dose 25μg NVX/M1+Placebo-D0/21 | |||||||
| 2 dose 25μg NVX/M1-D0/21 | 1 dose 25μg NVX/M1+Placebo-D0/21 | |||||||
| NCT04412538 Pu J, MedRxiv, 2020 Full text Commentary |
Public/non profit (Sponsor: Chinese Academy of Medical Sciences) |
KMS-1 D0/14 | Adjuvant | RCT | Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China. | N=96 |
Some concerns Details |
|
| KMS-1 D0/28 | Adjuvant | |||||||
| NCT04436276 Sadoff J, MedRxiv, 2020 Full text Commentary |
Mixed (Sponsor: Janssen Vaccines & Prevention B.V. ) |
Ad26.COV2.S 5x10^10vp 18-55y | Placebo | RCT | Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US | N=380 |
High Details |
|
| Ad26.COV2.S >65y | Placebo | |||||||
| NCT04368728 Walsh E, MedRxiv, 2020 Full text Commentary |
Private (Sponsor: BioNTech) | BNT162b1 D1/21 18-55y | Placebo | RCT | Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA | N=60 |
Some concerns Details |
|
| BNT162b1 D1/21 >65y | Placebo | |||||||
| BNT162b2 D1/21 18-55y | Placebo | |||||||
| BNT162b2 D1/21 >65y | Placebo | |||||||
| ChiCTR2000031809 Xia S, JAMA, 2020 Full text Commentary |
Mixed (Sponsor: China National Biotec Group & Wuhan Institute of Biological Products ) |
Inactivated 2.5μg-D0/28/56 | Adjuvant | RCT | Healthy adults, aged 18 to 59 years, without history of SARS-CoV (via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test) | N=96 |
Low Details |
|
| Inactivated 5μg-D0/28/56 | Adjuvant | |||||||
| Inactivated 10μg-D0/28/56 | Adjuvant | |||||||
| Inactivated 2.5μg-D0/28/56 | Inactivated 5μg-D0/28/56 | |||||||
| Inactivated 2.5μg-D0/28/56 | Inactivated 10μg-D0/28/56 | |||||||
| Inactivated 5μg-D0/28/56 | Inactivated 10μg-D0/28/56 | |||||||
| Inactivated 5μg-D0/14 | Adjuvant | |||||||
| Inactivated 5μg-D0/21 | Adjuvant | |||||||
| ChiCTR2000032459 Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Mixed (Sponsor: Henan Provincial Center for Disease Control and Prevention) |
Inactivated SARS-CoV-2 vaccine, 1-dose 8 ?g, Day 0 | Aluminum hydroxide adjuvant | RCT | Healthy SARS-CoV-2 serology negative adults 18-59 years old and ?60 years old in a single centre in China | N=112 |
Some concerns Details |
|
| Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/14 | Aluminum hydroxide adjuvant | |||||||
| Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/21 | Aluminum hydroxide adjuvant | |||||||
| Inactivated SARS-CoV-2 vaccine, 2-dose 4 ?g, Days 0/28 | Aluminum hydroxide adjuvant | |||||||
| NCT04352608 Zhang Y, MedRxiv, 2020 Full text Commentary |
Mixed (Sponsor: Sinovac Biotech Co., Ltd) |
Corona Vac 3μg-D0/14 | Adjuvant | RCT | Healthy volunteers aged 18-59, negative in COVID-19 serum antibodies and SARS CoV-2 infection-free, in a single centre in China. | N=300 |
Some concerns Details |
|
| Corona Vac 6μg-D0/14 | Adjuvant | |||||||
| Corona Vac 3μg-D0/14 | Corona Vac 6μg-D0/14 | |||||||
| Corona Vac 3μg-D0/28 | Adjuvant | |||||||
| Corona Vac 6μg-D0/28 | Adjuvant | |||||||
| Corona Vac 3μg-D0/28 | Corona Vac 6μg-D0/28 | |||||||
| NCT04341389 Zhu F, The Lancet, 2020 Full text Commentary Commentary |
Mixed(National Science and Technology Major Project, CanSino Biologics.) | Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp | Placebo | RCT | Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. | N=508 |
Some concerns Details |
|
| Adenovirus type-5-vectored COVID-19 5×10¹° vp | Placebo | |||||||
| Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp | Adenovirus type-5-vectored COVID-19 5×10¹° vp | |||||||